Duogenic Stemcells Corp. engages in the provision of biotechnology and medical care services. It offers closed culture cell system and cell therapy services. The company was founded on March 22, 2018 and is headquartered in Taichung, Taiwan.
7607 stock has risen by 0.30% compared to the previous week, the month change is a 0.15% fall, over the last year DUOGENIC STEMCELLS CORP has showed a 37.59% decrease.
7607 net income for the last quarter is −23.27 M TWD, while the quarter before that showed −21.97 M TWD of net income which accounts for −5.91% change. Track more DUOGENIC STEMCELLS CORP financial stats to get the full picture.
No, 7607 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 7607 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DUOGENIC STEMCELLS CORP stock right from TradingView charts — choose your broker and connect to your account.
7607 reached its all-time high on May 25, 2023 with the price of 65.10 TWD, and its all-time low was 30.95 TWD and was reached on Jun 20, 2023. See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DUOGENIC STEMCELLS CORP technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DUOGENIC STEMCELLS CORP stock shows the neutral signal. See more of DUOGENIC STEMCELLS CORP technicals for a more comprehensive analysis. If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DUOGENIC STEMCELLS CORP EBITDA is −37.87 M TWD, and current EBITDA margin is −277.11%. See more stats in DUOGENIC STEMCELLS CORP financial statements.